Benefits of Surgical Treatment in patients of Allergy with Nasal Problems

Efficacy of Sub-Mucosal Diathermy in patients of Allergic Rhinitis in a Tertiary Care Hospital in Rural Central India - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093562

Enrollment

Registered

2025-08-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Allergic testing and SMD procedure: Pre-operative Serum IgE Levels and Skin Prick Test followed by SMD Procedure followed by post-operative IgE levels at 4 weeks, 6weeks and 8 Weeks dur

Eligibility

Inclusion criteria

Inclusion criteria: All the consecutive/sequential patients in the age group of 5 yrs to 70 years with nasal or nasal complaints, diagnosed with allergic rhinitis, regardless of gender, and ethnicity, who shall undergo Sub-Mucosal Diathermy (SMD), presenting to ENT outpatient department, ENT ward or casualty of AVBRH, Sawangi (Meghe). ‘

Exclusion criteria

Exclusion criteria: Dermographism 2. Life threatening anaphylaxis 3. Uncooperative patients 4. Immunocompromised state 5. Patients on high dose of steroids 6. Patients with contraindications to SMD such as coagulation disorders, psychiatric ailments etc

Design outcomes

Primary

Measure	Time frame
Improvement in Nasal Patency and Symptom Severity: Assessed using SNOT-22 criteria for nasal obstruction, discharge, hyposmia, and allergies. Changes in SNOT-22 scores before and after Sub-Mucosal Diathermy (SMD) measure improvementsTimepoint: After pre-operative estimation of Serum IgE levels and Skin Prick Test, patients will be followed up with Serial IgE levels at 4 weeks, 6 weeks and 8 weeks to evaluate the efficacy of SMD in patients of Allergic Rhinitis	—

Measure

Time frame

Improvement in Nasal Patency and Symptom Severity: Assessed using SNOT-22 criteria for nasal obstruction, discharge, hyposmia, and allergies. Changes in SNOT-22 scores before and after Sub-Mucosal Diathermy (SMD) measure improvementsTimepoint: After pre-operative estimation of Serum IgE levels and Skin Prick Test, patients will be followed up with Serial IgE levels at 4 weeks, 6 weeks and 8 weeks to evaluate the efficacy of SMD in patients of Allergic Rhinitis

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Abhijeet Sharma

Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research (DMIHER)

drprasaddeshmukh1967@gmail.com9765404133

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026